Untangling the genetic basis of drug response

References

• 1. Timpson NJ, Greenwood CMT, Soranzo N, Lawson DJ, Richards JB. Genetic architecture: the shape of the genetic contribution to human traits and disease. Nat. Rev. Genet. 19(2), 110–124 (2018).
  Medline CASGoogle Scholar
• 2. Auton A, Abecasis GR, Altshuler DM et al. A global reference for human genetic variation. Nature 526(7571), 68–74 (2015).
  MedlineGoogle Scholar
• 3. Buniello A, Macarthur JAL, Cerezo M et al. The NHGRI-EBI GWAS catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res. 47(D1), D1005–D1012 (2019).
  Medline CASGoogle Scholar
• 4. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat. Rev. Drug Discov. 3(9), 739–748 (2004).
  Medline CASGoogle Scholar
• 5. Alfirevic A, Pirmohamed M. Genomics of adverse drug reactions. Trends Pharmacol. Sci. 38(1), 100–109 (2017).
  Medline CASGoogle Scholar
• 6. Bycroft C, Elliott LT, Young A et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562(7726), 203–209 (2018).
  Medline CASGoogle Scholar
• 7. Khera AV, Chaffin M, Aragam KG et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 50(9), 1219–1224 (2018).
  Medline CASGoogle Scholar
• 8. Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature 538(7624), 161–164 (2016).
  Medline CASGoogle Scholar
• 9. Martin AR, Gignoux CR, Walters RK et al. Human demographic history impacts genetic risk prediction across diverse populations. Am. J. Hum. Genet. 100(4), 635–649 (2017).
  Medline CASGoogle Scholar
• 10. Kim MS, Patel KP, Teng AK, Berens AJ, Lachance J. Genetic disease risks can be misestimated across global populations. Genome Biol. 19(1), 179 (2018).
  MedlineGoogle Scholar
• 11. Kerminen S, Martin AR, Koskela J et al. Geographic variation and bias in the polygenic scores of complex diseases and traits in Finland. Am. J. Hum. Genet. 104(6), 1169–1181 (2019).
  Medline CASGoogle Scholar
• 12. Rohde PD, Demontis D, Cuyabano BCD. The GEMS Group, Børglum AD, Sørensen P. Covariance Association Test (CVAT) identify genetic markers associated with schizophrenia in functionally associated biological processes. Genetics 203(4), 1901–1913 (2016).
  MedlineGoogle Scholar
• 13. Rohde PD, Sørensen IF, Sørensen P. qgg: an R package for large-scale quantitative genetic analyses. Prepr. BioRxiv doi:10.1101/503631 (2019).
  Google Scholar
• 14. Lango Allen H, Estrada K, Lettre G et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature 467, 832–838 (2010).
  MedlineGoogle Scholar
• 15. Lage K, Greenway SC, Rosenfeld JA, Wakimoto H, Gorham JM. Genetic and environmental risk factors in congenital heart disease functionally converge in protein networks driving heart development. Proc. Natl Acad. Sci. USA 109(35), 14035–14040 (2012).
  Medline CASGoogle Scholar
• 16. Maurano MT, Humbert R, Rynes E et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 337, 1190–1196 (2012).
  Medline CASGoogle Scholar
• 17. Rohde PD, Jensen IR, Sarup PM et al. Genetic signatures of drug response variability in Drosophila melanogaster. Genetics 213, 633–650 (2019).
  Medline CASGoogle Scholar
• 18. Huang W, Massouras A, Inoue Y et al. Natural variation in genome architecture among 205 Drosophila melanogaster genetic reference panel lines. Genome Res. 24(7), 1193–1208 (2014).
  Medline CASGoogle Scholar
• 19. Robinson JR, Denny JC, Roden DM, Van Driest SL. Genome-wide and phenome-wide approaches to understand variable drug actions in electronic health records. Clin. Transl. Sci. 11(2), 112–122 (2018).
  MedlineGoogle Scholar
• 20. Giacomini KM, Yee SW, Mushiroda T, Weinshilboum RM, Ratain MJ, Kubo M. Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine. Nat. Rev. Drug Discov. 16(1), 1 (2016).
  MedlineGoogle Scholar